Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

被引：0

作者：

Ritchlin, Christopher T. ^{[1
]}

Rahman, Proton ^{[2
]}

Helliwell, Philip S. ^{[3
]}

Boehncke, Wolf-Henning ^{[4
]}

McInnes, Iain ^{[5
]}

Gottlieb, Alice B. ^{[6
]}

Kollmeier, Alexa P. ^{[7
]}

Shawi, May ^{[8
]}

Zhou, Bei ^{[7
]}

Mease, Philip J. ^{[9
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[2] Mem Univ Newfoundland, St John, NF, Canada

[3] Univ Leeds, Leeds, W Yorkshire, England

[4] Geneva Univ Hosp, Geneva, Switzerland

[5] Univ Glasgow, Glasgow, Lanark, Scotland

[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

[7] Janssen Res & Dev LLC, Raritan, NJ USA

[8] Janssen Global Serv LLC, Raritan, NJ USA

[9] Univ Washington, Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA 98195 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

27529

引用

页码：AB151 / AB151

页数：1

共 50 条

[41] Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Reich, Kristian
Dutz, Jan
Foley, Peter
Thaci, Diamant
Vender, Ron
Song, Michael
Miller, Megan
Yu, Yin
Li, Shu
Shen, Yaung-Kaung
Armstrong, April W.
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[42] Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years
Rahman, Proton
Ritchlin, Christopher
Mease, Philip
Helliwell, Philip
Boehncke, Wolf-Henning
McInnes, Iain
Shawi, May
Marrache, Marilise
Kollmeier, Alexa
Xu, Lillian
Yu, Jenny
Wang, Yanli
Gottlieb, Alice
JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 774 - 775
[43] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1126, 2020)
Mease, P. J.
Rahman, P.
Gottlieb, A. B.
LANCET, 2020, 395 (10230): : 1114 - 1114
[44] Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
Rahman, Proton
Ritchlin, Christopher
Mease, Philip
Helliwell, Philip S.
Boehncke, Wolf-Henning
McInnes, Iain
Shawi, May
Marrache, Anne Marilise
Kollmeier, Alexa
Xu, Xie
Yu, Jenny
Wang, Yanli
Sheng, Shihong
Gottlieb, Alice
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3757 - 3759
[45] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Deodhar, Atul
Helliwell, Philip S.
Boehncke, Wolf-Henning
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Subramanian, Ramanand A.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
Ritchlin, Christopher T.
LANCET, 2020, 395 (10230): : 1115 - 1125
[46] Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Orbai, Ana-Maria
Coates, Laura
Deodhar, Atul
Helliwell, Philip
Ritchlin, Christopher
Kollmeier, Alexa
Hsia, Elizabeth
Xu, Xie
Sheng, Shihong
Zhou, Bei
Han, Chenglong
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[47] GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1
Orbai, A. M.
Coates, L. C.
Deodhar, A.
Helliwell, P.
Ritchlin, C. T.
Kollmeier, A.
Hsia, E. C.
Xu, X. L.
Sheng, S.
Zhou, B.
Han, C.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1704 - 1705
[48] Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
Pushpike Thilakarathne
Agata Schubert
Steve Peterson
Wim Noel
Barkha P. Patel
Fareen Hassan
Rheumatology and Therapy, 2024, 11 : 457 - 474
[49] IN PHASE-3 TRIALS DISCOVER 1 AND 2, GUSELKUMAB REDUCED FATIGUE OVER 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND DEMONSTRATED INDEPENDENT TREATMENT EFFECTS ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR 20)
Rahman, Proton
Helliwell, Philip
Deodhar, Atul
Kollmeier, Alexa
Hsia, Elizabeth
Zhou, Bei
Lin, Xiwu
Han, Chenglang
Mease, Philip
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S107 - S108
[50] Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
Thilakarathne, Pushpike
Schubert, Agata
Peterson, Steve
Noel, Wim
Patel, Barkha P.
Hassan, Fareen
RHEUMATOLOGY AND THERAPY, 2024, 11 (02) : 457 - 474

← 1 2 3 4 5 →